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Overcoming cut-off restrictions in multimorbidity
prevalence estimates
Barbara M Holzer1,4*, Klarissa Siebenhuener1,4, Matthias Bopp2,4 and Christoph E Minder3
Abstract
Background: Presently, there is no consensus on how to define multimorbidity. In this paper we investigate the
connection between prevalence estimates for two or more and three or more chronic conditions to improve
comparability of multimorbidity studies with different cut-offs.
Methods: In a systematic review of the literature published between January, 1990 and December, 2011, we found
52 suitable studies, many providing prevalence estimates for several age groups. A total of 31 studies reported both
the prevalence for multimorbidity based on two or more chronic conditions and three or more chronic conditions,
which were analysed in this study. Our research question was whether there is a systematic interrelation between
these two prevalence estimates, and how this could be used to improve the comparability of studies on the
burden of multimorbidity.
Results: Actually, we found a tight relationship between the prevalence of two or more and three or more chronic
conditions. Moreover, each of these estimates can be predicted from the other. I.e. the cut-offs of two or three for
the number of chronic conditions produce essentially the same information on prevalence.
Conclusions: Our study shows a way to enhance and improve the comparability of prevalence estimates from
different multimorbidity studies.
Keywords: Comorbidity, Multimorbidity, Definition, Operationalization, Multiple chronic conditions, Systematic
review
Background
Multimorbidity is commonly defined as the co-occu-
rrence of more than one chronic disease or chronic
medical conditions in one person. This concept was in-
troduced by van den Akker in a theoretical article with
the aim to distinguish multimorbidity from comorbidity,
where the focus lies on an index disease [1].
Numerous studies in many countries on prevalence of
multimorbidity have been based on this concept of co-
occurrence of several chronic diseases [2-6]. However,
due to the absence of a widely accepted operationa-
lization of multimorbidity, the comparability of these
studies remains questionable. Known factors influencing
prevalence estimates include the patient’s age, the num-
ber and the exact list of chronic conditions considered,
and the minimum number of conditions required [7]. As
a consequence, estimates of the prevalence of multimor-
bidity vary widely, e.g. from 13.1% to 71.8% for two or
more chronic conditions in the general population or
from nearly 0% to 95% for three or more chronic condi-
tions in primary care populations [8].
Nevertheless, the simple count of chronic conditions
not only provides a measure of prevalence, but is also
the most commonly used approach to express the bur-
den of multimorbidity [9]. Other widely used measures
such as the Charlson Index or the Cumulative Illness
Rating Scale (CIRS) are more complex and need more
detailed data [10,11], making them less suitable for a sys-
tematic review.
So far, the majority of researchers did use a cut-off
point of two chronic conditions, with notable exceptions
[12-14]. About a quarter of the studies presented esti-
mates of prevalence of multimorbidity based on cut-offs
2+ and 3+ conditions and about half of these studies
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presented additional cut-offs of 4+ or/and 5+ chronic
conditions [4,15,16].
Our study had three principal aims. Based on the data
available from the systematic review mentioned above,
we wanted
(1)to explore the relationship between the prevalence
of two or more chronic conditions (P2+) and that of
three or more chronic conditions (P3+)
(2)to find factors affecting the prevalence of two or
more chronic conditions (P2+), given the prevalence
of three or more chronic conditions (P3+) in the
same study
(3)on the basis of the above, and since P2+ is most
commonly reported, to find a way to estimate the
prevalence of two or more chronic conditions (P2+)
in studies where only the prevalence of three or
more chronic conditions (P3+) is available.
Methods
Data collection
Data for this study were obtained through a systematic re-
view of the literature using MEDLINE/PreMEDLINE and
Embase databases, CINAHL, the Web of Science and
BIOSIS databases, and Google Scholar. We looked for
relevant articles published in English or German between
January, 1990 and December, 2011. For each database we
used search strategies with the terms “multimorbidity” or
“comorbidity” or “polymorbidity” and variations of these
(see Additional file 1 for more information). Details re-
garding the search strategy and the criteria defined for
evaluation were described elsewhere [17]. We included
original studies addressing multimorbidity (no index-
disease) with a sample size not smaller than 50. For better
comparability, only study populations with a proportion of
at least 50% Caucasians were included. The methods sec-
tion had to satisfy scientific standards, in particular the
chronic conditions selected and the prevalence of two or
more (P2+) and three or more (P3+) chronic conditions
estimates had to be identifiable. Studies were also included
when one of these prevalence estimates was missing, but
could be calculated from information given in the articles.
Furthermore, the sample size of the study population as
well as the description of the setting had to be reported.
We compiled a database containing data of 52 studies.
Figure 1 shows the flow diagram [18] according to
PRISMA standards. We applied the PRISMA checklist as
far as possible (see Additional file 2).
Most of the studies reported prevalence estimates for
several age groups. A total of 31 studies reporting both,
the prevalence of multimorbidity based on two or more
(P2+) chronic conditions and three or more (P3+)
chronic conditions remained for the present analysis,
contributing 72 pairs of prevalence estimates, one for
each age group or population in the study, including a
total of about 10 million cases (details see Additional file
3). All 31 articles fulfilled at least 12 of the 22 possible
quality items of the STROBE checklist (Strengthening
the Reporting of Observational studies in Epidemiology)
[19], as was previously suggested by Fortin [8].
In cases where explicit prevalence estimates per age
group were missing and could not be derived from esti-
mates given, we calculated prevalence based on infor-
mation in the paper (e.g. size of the age group and
number of multimorbid patients) or even in background
papers referenced in the relevant study (15 articles). E.g.
we added given estimates for 2, 3, 4, 5 and more chronic
conditions together to get the two plus and three plus
prevalence for each available age group.
For papers with only separate estimates by gender, we
calculated weighted mean values and subsequently the
overall mean per age group (4 articles). Furthermore, we
obtained adequate estimates by calculating the size
of the respective age group using the WHO-standard
population (1 article) or by reading the prevalence of
two plus and three plus chronic conditions out of graphs
(1 article).
If mean age of the age group(s) was not indicated in
the paper, it was derived from gender-specific one-year
age-class general population data in the respective coun-
try and study period [20].
Statistical analysis
Prevalence data for two or more (P2+) as well as three
and more (P3+) chronic conditions were extracted from
all studies in the systematic review reporting both pre-
valence estimates. These 72 pairs of prevalence estimates
were converted into percentages and compared gra-
phically. To obtain an adequate model for predicting logit
P2+, we used a modified version of backward elimination
to select the variables to be retained. Beginning with a full
model including 8 factors and 30 parameters, we suc-
cessively eliminated non-significant factors and grouped
levels with similar effects within factors, simultaneously
checking the criteria t2, I2, R2 (adjusted) and model F. We
ended up with 2 competing models, one with 5 and one
with 6 parameters. For the purpose of prediction, we then
chose the more parsimonious model with the 5 predictors.
Data were prepared using Microsoft Excel®. Statistical ana-
lyses and graphs were done with Stata 12.1. Model fitting
was done using the Stata metareg procedure.
Results
A total of 31 studies reported estimates of prevalence of
P2+ and P3+ chronic conditions for a total of 72 preva-
lence groups (populations or age groups). Thus, the 31
studies contributed 72 pairs of prevalence estimates,
each pair consisting of an estimate for P2+ and P3+
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chronic conditions. A table presenting salient informa-
tion regarding the studies and age groups included in
the analysis is given in Additional file 3.
Figure 2 presents the first main finding: There is a
tight relationship between the prevalence estimates of
two or more versus three or more chronic conditions,
despite obvious and very substantial variation between
studies in populations, definitions, study designs etc.
The tight relationship visible in Figure 2 permitted us to
fit a statistical model relating P2+ to P3+. An initial model
for predicting P2+ was set up with the following variables
as predictors: P3+, study setting (GP practice, general
population, health insurance), duration of study (0 to
10 yrs), number of age groups in study (1 to 5), span of
age group (4 to 90 yrs, average 29.0), mean age of age
group (12.8 yrs to 89.3 yrs, mean 59.5), data quality (rated
as original data, or as calculated from data presented in
the paper or as estimates read out from graphs), number
of chronic conditions considered (5 up to more than 300),
type of classification (ICD, ICPC-2, other).
Using these variables, a model suitable for predic-
ting logit P2+ was found by elimination of insignificant
variables and coarser grouping if there were only small ef-
fect differences between adjacent levels of the finer grou-
ping of class variables. The continuous variables mean age
of age group and P3+ were also squared. The final model
contained the predictors logit P3+, mean age, whether the
number of age groups exceeded 2 or not, and whether the
number of conditions in the list considered was less than
20, between 20 and 99, or 100 or larger (Table 1).
The model fit was good: F (5, 66) = 322, R2 = 97.7%
(adjusted), excess variability due to heterogeneity τ = 0.4068.
The standard error of prediction (logit scale) of this model
was 0.219 and essentially constant over the range, leading
to the prediction limits and best predictions shown in
Table 2.
I. e. in the worst situation (predicted logit = 0) the
width of the prediction interval for the prevalence is
22% (39% to 61%). For all other values, the width is nar-
rower. Using Table 2, studies providing P3+ only and
not P2+ can now be compared to studies giving P2+
only. For small and large values of P3+ this comparison
is precise, while for middle values of P3+ around 0.5 the
precision is lower.
Records identified through database searching
(n = 4464): 
Pubmed/Medline = 1526
Embase = 1666
Web of Science = 631
BIOSIS = 265
CINAHL = 101
Google scholar = 275
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Additional records identified through other sources 
(n = 4)
Records screened
(including database searching Nov-Dec 2011)
(n = 4468) 
Records excluded 
(n = 4394) 
Full-text articles assessed for eligibility 
(n = 74) 
Full-text articles excluded, 
due to application of detailed exclusion criteria
(n = 22) 
Studies included in qualitative synthesis 
(n = 52) 
Studies included in quantitative synthesis 
(n = 31)
Full-text articles excluded, 
did not include all data required for analysis 
(P2+ and P3+ estimates)
(n=21)
Figure 1 PRISMA flow diagram of the evaluation process.
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To estimate a value for P2+ when only P3+ is given,
proceed as follows. First, compute the value of the logit
predictor applicable to the study using Table 1. With the
value so computed, enter Table 2 in the appropriate line.
Interpolation is acceptable. Example: A study in question
with three age groups and based on 35 chronic conditions
provided P3 + = 0.2 for the age group 20-39 (mean age of
30 years). Logit P3 + = logit 0.2 is -1.3863 and from Table 1,
the linear predictor of logit P2+ is 0.04704 + (0.74285*
(-1.3863)) + 0.23345 + (0.01055*30) + (-0.14314) = -0.57596.
Using Table 2 with the value -0.576, one obtains a best
estimate of P2+ of 0.36, and a 95% interval of prediction
from 0.26 to 0.46 (lower to upper limit).
Discussion
The simple count of chronic conditions is still the most
common approach to express and measure the burden of
multimorbidity [9]. In our study a basic element of this
approach was examined: The cut-off point of two vs. three
chronic conditions. To our knowledge, so far no study
investigated this topic. One other article (a systematic re-
view) did consider this point but not with statistical
methods [8]. Our analysis shows that the relationship bet-
ween P2+ and P3+ is influenced by the factors age, num-
ber of age groups and size of the list of chronic conditions
considered in the study; in our data set, P3+ was the most
influential factor, followed by mean age, the number
of age groups in the study and the number of chronic
Figure 2 Prevalence of multimorbidity in 72 prevalence groups (populations or age groups) from 31 studies. All studies with prevalence
estimates for two or more (P2+) and three or more (P3+) chronic conditions were shown. The index numbers give the number of the study from
which the prevalence estimates originated (see Additional file 3).
Table 1 Random effects logit model relating the prevalence
of P2+ or P3+
Predictor for logit P2+ Coefficient Std.Error t-value p-value
Constant 0.04704 0.17429 0.27 0.788
Logit P3+ 0.74285 0.02802 26.52 <0.0005
Nr of age groups > 2 0.23345 0.07435 3.14 0.003
Mean age 0.01055 0.002387 4.42 <0.0005
20-99 chronic conditions -0.14314 0.084165 -1.7 0.094
≥100 chronic conditions 0.30834 0.11928 2.59 0.012
N = 72 prevalence groups (populations or age groups) from 31 studies.
Legend: logit P2 + = logit prevalence of 2 or more chronic conditions.
logit P3 + = logit prevalence of 3 or more chronic conditions.
Table 2 Best predictions and 95% prediction intervals
derived from model
Predicted (logit) logit P2+ P2+
(best fit) Low High Low Best High
-5 -5.43 -4.57 0 0.007 0.01
-4 -4.43 -3.57 0.01 0.018 0.027
-3 -3.43 -2.57 0.03 0.047 0.071
-2 -2.43 -1.57 0.08 0.119 0.172
-1.5 -1.93 -1.07 0.13 0.182 0.255
-1 -1.43 -0.57 0.19 0.27 0.36
-0.5 -0.93 -0.07 0.28 0.38 0.48
0 -0.43 0.43 0.39 0.5 0.61
0.5 0.07 0.93 0.52 0.62 0.72
1 0.57 1.43 0.64 0.73 0.81
1.5 1.07 1.93 0.74 0.82 0.87
2 1.57 2.43 0.83 0.881 0.919
3 2.57 3.43 0.93 0.953 0.969
4 3.57 4.43 0.97 0.982 0.988
5 4.57 5.43 0.99 0.993 0.996
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conditions in the list. Number of age groups and number
of chronic conditions were of about equal importance.
Likely, the number of age groups in the study is a proxy
for several effects: a small number of age groups may
mean that only one or two wide age groups were consi-
dered. Alternatively, it could mean that the study gives
only an age selected view of the situation.
Other proposed indices to measure the burden of mul-
timorbidity are the Charlson Index [21], the Cumulative
Illness Rating Scale [22], or concepts used in specific soft-
ware to evaluate quality of outcomes, resource utilization
such as the Johns Hopkins University Adjusted Clinical
Groups (ACG®) Case-Mix System [23]. These measures
are substantially more complex and geared to different
purposes, thus not useful to determine the prevalence of
multimorbidity in a population.
Our study has several weaknesses. As in any syste-
matic review, not all factors of interest can be investi-
gated, the notable example here being gender. Only very
few studies were either covering one gender only, or
looking at both gender separately.
The studies considered varied considerably in the quality
of their reporting and probably execution. E.g. the popu-
lation investigated was often described very sketchily,
sometimes even the number of patients per age group was
missing. The tight relationship presented in Figure 2 is
quite surprising in view of the considerable heterogeneity
of studies. We decided to use the simplest possible predic-
tion model. As Figure 2 shows, nevertheless this model is
fitting rather well. We therefore expect that the predic-
tions derived from it to prove reliable. Our approach is not
the only one feasible. Of course, one could also predict
P3+ from P2+. Another approach would be to develop
a joint prediction model for P2+ and P3+ and to use
Bayesian methods to predict P2+ when only P3+ was
known (and vice versa).
So far, most authors have used a cut-off of 2+ for the
number of chronic conditions. In order to exploit studies
with only a cut-off of 3+, we added Table 2 which helps
finding an approximate corresponding prevalence for a
cut-off of 2+, given a cut-off of 3+. In this paper we
present evidence that cut-offs 2+ and 3+ for the number
of chronic conditions provide essentially the same infor-
mation on prevalence. If the prevalence estimates for a
cut-off of 3+ chronic conditions is known, the prevalence
for 2+, and possibly other cut-offs, may be estimated and
vice versa. Hence, if one is interested in comparing preva-
lence estimates of multimorbidity, much of the discussion
on whether a cut-off of 2+ or 3+ chronic conditions is
more appropriate [8] becomes redundant.
In the broader discussion on how to operationalize
and measure multimorbidity, many factors were men-
tioned, such as age, gender, the number and types of
chronic conditions included, and factors concerning the
setting and data collection methods [7-9,24]. Our study
established that, apart from the cut-off, the number of
chronic conditions included as well as mean age and the
number (and possibly the width) of age groups in the
study, are of importance. We see great potential for im-
proving comparability by agreeing on the most impor-
tant factors to be routinely reported.
Conclusions
Our study is a step towards addressing the problem of
the comparability of prevalence estimates in the context
of determining the burden of multimorbidity in a popu-
lation. In a next step, other fundamental determinants of
the prevalence (setting, age, gender, geographical area)
have to be examined in order to contribute to the dis-
cussion on how to define and operationalize multimor-
bidity in epidemiological research.
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